Interferon beta-1b biosimilar - Amega Biotech/Actover Pharmaceutical

Drug Profile

Interferon beta-1b biosimilar - Amega Biotech/Actover Pharmaceutical

Alternative Names: Actoferon

Latest Information Update: 14 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amega Biotech
  • Developer Actover Pharmaceutical; Amega Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 14 Aug 2013 Investigation in Multiple sclerosis in Argentina (SC)
  • 01 Jan 2013 Launched for Multiple sclerosis in Iran (SC)
  • 20 Oct 2011 Actover Pharmaceutical initiates enrolment in a phase III trial for Multiple sclerosis in Iran (IRCT2013030512398N2)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top